Mitralign To Highlight TrialignTM System at EuroPCR 2016
Company Sponsored Symposium on Thursday, May 19: Trialign
Transcatheter Annuloplasty for the treatment of tricuspid regurgitation
TEWKSBURY, Mass.–(BUSINESS WIRE)–Mitralign Inc. an innovative developer of direct transcatheter mitral
and tricuspid valve repair solutions will present its TrialignTM
System for transcatheter tricuspid repair at the EuroPCR conference, one
of the world’s leading conferences on cardiology. EuroPCR takes place in
Paris, France at the Palais des Congrès from May 17 – 20.
Mitralign will be highlighted at the EuroPCR Innovators Day on May 16th,
with Dr. Azeem Latib, from St. Rafaelle Hospital presenting the Trialign
System for the treatment of tricuspid regurgitation. In addition, the
company will sponsor a symposium on Thursday, May 19th
chaired by Dr. Neil Moat, of the Royal Brompton Hospital, London, UK.
The symposium will be held from 13:35 – 14:35 in room 241. Mitralign
personnel will be available in the Palais de Congrès at booth P13
located on the second floor.
Mitralign is the only company to provide a direct transcatheter
annuloplasty system, designed to treat both functional mitral
regurgitation (FMR) and functional tricuspid regurgitation (FTR). The
first application of this innovation, the Mitralign Percutaneous
Annuloplasty System (MPAS) for FMR, earned CE Mark earlier this year.
Trialign for FTR is being investigated in an early feasibility study in
the US and is not approved for sale or distribution.
About Tricuspid Regurgitation (FTR)
Tricuspid regurgitation
occurs when the tricuspid valve fails to open and close properly,
causing blood to flow backwards into the right atrium. If left
untreated, TR can lead to heart enlargement and heart failure. In the
U.S. alone, there are an estimated 1.6 million patients suffering from TR4.
It is estimated that 50% of patients with mitral regurgitation have
moderate to severe tricuspid regurgitation5. TR is currently
undertreated by surgery. In the U.S. surgeons treat only 5,500 patients
per year, most of them in conjunction with left heart surgeries. When
treating the valves, surgeons choose repair 90% of the time versus
replacement (10%)4.
About Functional Mitral Regurgitation (FMR)
The mitral
valve controls blood flow from the left atrium to the left ventricle
of the heart, allowing blood to flow in one direction through the heart
and into the body. Functional Mitral Regurgitation (FMR) is the most
common valve disease and occurs when the left ventricle of the heart is
enlarged and stretches the valve open. Subsequent to this remodeling,
the valve leaflets are not able to come together and close properly,
allowing blood to flow, or regurgitate, backwards into the atrium.
Consequences can include heart failure or serious rhythm problems called
arrhythmias. An estimated four million people in Europe and four million
people in the United States have significant mitral valve insufficiency,
also known as mitral regurgitation, with an annual incidence of 250,0003.
If left untreated, mitral regurgitation overloads the heart and can lead
to or accelerate heart failure.
About Mitralign Inc.
Mitralign Inc. is the valve repair
company with the only direct transcatheter annuloplasty system designed
to treat both functional mitral regurgitation and tricuspid
regurgitation. The company, a leader in transcatheter repair for
tricuspid regurgitation, is a venture-backed, medical innovation company
located near Boston, Massachusetts, USA. For more information, visit www.mitralign.com.
1. Jamieson WR, Edwards FH, Schwartz M, et al. Ann Thorac Surg
1999;67:943-951
2. Stuge O., Liddicoat J., et al. JTCS
2006;132:1258-61
3. Argarwal et al. Circ Cardiovasc Interv
2009;2:565-573
4. RogersJH.Circulation2009:119: 2718-25
Contacts
Mitralign Inc.
David Schleifer, 617-869-6166
Vice
President, Marketing
dschleifer@mitralign.com
